source
- Amneal to acquire biosimilar maker for $375 million upfrontAmneal Pharmaceuticals announced it will purchase a biosimilar development company, agreeing to pay $375 million in an upfront cash payment. The deal expands Amneal’s portfolio in the growing biosi…
- CAR-T biotech Kelonia rebounds from cash crises to a $3 billion sale, while drugmakers explore Prescribery partnershipThe latest episode of STAT's "The Readout LOUD" podcast focuses on a dramatic turnaround at a CAR‑T biotech that faced near‑bankruptcy three times before being bought for more than $3 billion. The…